NASDAQ:DARE Daré Bioscience (DARE) Stock Price, News & Analysis $3.63 +0.03 (+0.83%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.55▼$3.6450-Day Range$3.09▼$7.3252-Week Range$3.05▼$9.47Volume9,111 shsAverage Volume49,163 shsMarket Capitalization$30.56 millionP/E RatioN/ADividend YieldN/APrice Target$54.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Daré Bioscience alerts: Email Address Daré Bioscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,387.6% Upside$54.00 Price TargetShort InterestHealthy0.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.57) to $1.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 starsMedical Sector738th out of 936 stocksPharmaceutical Preparations Industry343rd out of 436 stocks 3.3 Analyst's Opinion Consensus RatingDaré Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDaré Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Daré Bioscience's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.71% of the float of Daré Bioscience has been sold short.Short Interest Ratio / Days to CoverDaré Bioscience has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daré Bioscience has recently increased by 68.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDaré Bioscience does not currently pay a dividend.Dividend GrowthDaré Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DARE. Previous Next 1.8 News and Social Media Coverage News SentimentDaré Bioscience has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Daré Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for DARE on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daré Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Daré Bioscience is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of Daré Bioscience is held by institutions.Read more about Daré Bioscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Daré Bioscience are expected to grow in the coming year, from ($2.57) to $1.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Daré Bioscience is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Daré Bioscience is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Daré Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Daré Bioscience Stock (NASDAQ:DARE)Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Read More DARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DARE Stock News HeadlinesJuly 25 at 9:04 PM | msn.comMan with outstanding warrants accused of leading Dare County deputies on chaseJuly 23 at 6:25 PM | yahoo.comDare Co to implement Blue Envelope Program for people with conditions, disabilitiesJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 21, 2024 | msn.comIs Arike Ogunbowale Related to NFL's Dare Ogunbowale?July 20, 2024 | msn.comAdvocate plans to expand balloon release ban after its approval in Dare CountyJuly 20, 2024 | msn.comDare County Schools superintendent addresses ‘evolution of misinformation’ about early college high school plansJuly 19, 2024 | finanznachrichten.deDaré Bioscience, Inc.: Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price RuleJuly 19, 2024 | globenewswire.comDaré Bioscience Regains Compliance with Nasdaq Minimum Bid Price RuleJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 19, 2024 | americanbankingnews.comDaré Bioscience (NASDAQ:DARE) Stock Price Crosses Below 200 Day Moving Average of $4.73June 27, 2024 | globenewswire.comDaré Bioscience Announces Reverse Stock SplitMay 29, 2024 | yahoo.comDare To Love Me Episode 5 Recap & Spoilers: Is Lee Yoo-Young Jealous of the New Woman in Kim Myung-Soo’s Life?May 22, 2024 | yahoo.comDare To Love Me Episode 4 Trailer Teases Glimpses of Kim Myung-Soo & Lee Yoo-Young’s Simple LifeMay 18, 2024 | uk.investing.comDare Bioscience shares target cut, maintains buy ratingMay 16, 2024 | markets.businessinsider.comBuy Rating on Daré Bioscience: Promising Pipeline and Strategic Financial PositioningMay 16, 2024 | msn.comBrookline Capital Upgrades Daré Bioscience (DARE)May 15, 2024 | msn.comBrookline Capital upgrades Dare Bioscience, cites improved fundingMay 15, 2024 | finance.yahoo.comQ1 2024 Dare Bioscience Inc Earnings CallSee More Headlines Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DARE CUSIPN/A CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees23Year FoundedN/APrice Target and Rating Average Stock Price Target$54.00 High Stock Price Target$72.00 Low Stock Price Target$36.00 Potential Upside/Downside+1,383.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.8415) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,160,000.00 Net MarginsN/A Pretax Margin-1,024.96% Return on EquityN/A Return on Assets-139.90% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.56 Sales & Book Value Annual Sales$2.81 million Price / Sales10.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.61) per share Price / Book-5.97Miscellaneous Outstanding Shares8,420,000Free Float8,084,000Market Cap$30.65 million OptionableNot Optionable Beta1.37 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Sabrina Martucci Johnson (Age 57)CEO, President, Principal Financial Officer, Secretary & Director Comp: $804.07kMs. Lisa Walters-Hoffert (Age 65)Executive Officer Comp: $523.2kMr. Mark Walters (Age 69)Vice President of Operations Ms. MarDee J. Haring-Layton (Age 48)Chief Accounting Officer Dr. David FriendChief Scientific OfficerKey CompetitorsRecro PharmaNASDAQ:REPHCybinNYSE:CYBNRelmada TherapeuticsNASDAQ:RLMDInterCureNASDAQ:INCRTelomir PharmaceuticalsNASDAQ:TELOView All Competitors DARE Stock Analysis - Frequently Asked Questions How have DARE shares performed this year? Daré Bioscience's stock was trading at $3.7080 at the beginning of 2024. Since then, DARE shares have decreased by 2.1% and is now trading at $3.63. View the best growth stocks for 2024 here. How were Daré Bioscience's earnings last quarter? Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.12. The biotechnology company earned $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. When did Daré Bioscience's stock split? Daré Bioscience's stock reverse split before market open on Monday, July 1st 2024. The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Daré Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Daré Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB) and Novavax (NVAX). This page (NASDAQ:DARE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daré Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.